. Author manuscript; available in PMC: 2018 Feb 22.

Published in final edited form as: JAMA. 2010 Apr 21;303(15):1517–1525. doi: 10.1001/jama.2010.479

Table 4.

Impact of Trimester and Timing of Antiviral Treatment on Admission to an Intensive Care Unit Among Hospitalized Patients

Trimester and Treatment Timing^a	No. (%) of Women		Relative Risk (95% CI)	P Value
Trimester and Treatment Timing^a	Intensive Care Admission (n = 61)	No Intensive Care Admission (n = 192)	Relative Risk (95% CI)	P Value
Any trimester ≤2 d after symptom onset	13 (9.4)	125 (90.6)	1.0 [Referent]

3-4 d after symptom onset, trimester
First	1 (16.7)	5 (83.3)	1.8 (0.3-11.4)	.47^b

Second	3 (14.3)	18 (85.7)	1.5 (0.5-4.9)	.45^b

Third	9 (33.3)	18 (66.7)	3.5 (1.7-7.4)	.003^b

>4 d after symptom onset, trimester
First	3 (75.0)	1 (25.0)	8.0 (3.7-17.1)	.004^b

Second	14 (58.3)	10 (41.7)	6.2 (3.3-11.5)	<.001^b

Third	18 (54.5)	15 (45.5)	5.8 (3.2-10.6)	<.001

Abbreviation: CI, confidence interval.

Sixty-four pregnant women who were treated, but timing was unknown, and 89 with unknown treatment status were excluded from relative risk computations. Pregnant women receiving intermediate or late treatment with unknown pregnancy trimester (n=73) were also excluded.

Fisher exact test.